studi
gene
fusion
solid
tumor
extens
hematolog
malign
due
sever
technic
analyt
problem
associ
tumor
heterogen
nevertheless
grow
interest
role
fusion
gene
common
epitheli
tumor
discoveri
recurr
et
fusion
prostat
cancer
among
report
fusion
partner
et
gene
famili
erg
preval
one
present
simpl
sensit
microarraybas
assay
abl
simultan
determin
multipl
fusion
variant
singl
rtpcr
impur
rna
specimen
assay
detect
erg
fusion
transcript
detect
sensit
cell
presenc
time
excess
normal
rna
primari
prostat
tumor
cancer
cell
abil
detect
multipl
transcript
variant
singl
assay
critic
depend
primer
probe
design
assay
facilit
clinic
basic
studi
fusion
gene
screen
clinic
specimen
readili
adapt
includ
multipl
gene
loci
chromosom
rearrang
characterist
featur
cancer
gene
fusion
consequ
chromosom
aberr
identifi
gene
fusion
common
hematolog
malign
presenc
solid
tumor
well
studi
due
sever
technic
analyt
problem
relat
tumor
heterogen
limit
gene
fusion
event
discov
solid
tumor
mostli
sarcoma
recent
discoveri
et
fusion
gene
prostat
cancer
find
sinc
chang
gener
view
gene
fusion
play
minor
role
pathogenesi
epitheli
tumor
therefor
renew
interest
search
fusion
gene
solid
tumor
due
potenti
impact
basic
research
clinic
applic
demonstr
chronic
myelogen
leukemia
cml
recurr
gene
fusion
event
prostat
cancer
involv
androgen
control
gene
member
erg
et
transcript
factor
famili
among
fusion
gene
erg
preval
member
detect
major
report
fusion
transcript
result
mb
interstiti
delet
two
loci
chromosom
found
approxim
half
prostat
cancer
androgenrel
transcript
factor
control
cell
prolifer
erg
associ
diseas
pathogenesi
promis
biomark
prostat
cancer
progress
prognost
earli
detect
presenc
et
fusion
gene
highli
prostat
cancerspecif
signific
prognost
biomark
still
controversi
partli
mani
clinic
studi
rel
small
scale
therefor
import
develop
simpl
robust
assay
identifi
variou
et
potenti
fusion
gene
solid
tumor
howev
could
challeng
due
high
heterogen
prostat
cancer
solid
tumor
compar
leukemia
lymphoma
sever
approach
use
previous
hematolog
malign
appli
detect
erg
exon
fusion
variant
includ
fluoresc
situ
hybrid
fish
rtpcr
sequenc
quantit
pcr
qpcr
arraybas
compar
genom
hybrid
array
cgh
fish
may
commonli
use
method
rel
low
resolut
therefor
accur
determin
differ
fusion
variant
array
cgh
higher
resolut
costli
often
fail
normal
cell
contamin
rtpcr
qpcr
rel
easi
perform
howev
assess
multipl
potenti
fusion
variant
requir
multipl
set
primer
probe
correspond
larg
quantiti
rna
templat
moreov
sequenc
rtpcr
product
labori
difficult
adapt
routin
clinic
laboratori
describ
exon
arraybas
detect
system
combin
rtpcr
reaction
accur
determin
multipl
erg
fusion
transcript
specimen
minor
popul
tumor
cell
method
adopt
sever
featur
virochip
protocol
establish
specif
sensit
semiquantit
assay
use
analyz
highli
heterogen
solid
tumor
cell
line
describ
articl
obtain
american
type
cultur
collect
atcc
manassa
va
usa
cultur
recommend
frozen
unpurifi
prostat
tissu
obtain
routin
surgeri
classifi
patholog
one
us
total
rna
extract
trizol
invitrogen
carlsbad
ca
usa
follow
manufactur
instruct
primari
tumor
sampl
purifi
qiagen
rneasi
mini
kit
qiagen
valencia
ca
usa
exon
junction
probe
oligonucleotid
synthes
integr
dna
technolog
coralvil
ia
usa
illuminainvitrogen
san
diego
ca
usa
print
polyllysin
slide
mm
along
human
dna
invitrogen
enrich
repetit
sequenc
her
sperm
dna
promega
madison
wi
usa
use
nonspecif
control
print
procedur
describ
essenti
follow
manual
derisi
array
silicon
microcontact
print
pin
parallel
synthesi
technolog
inc
santa
clara
ca
usa
array
postprocess
succin
anhydridebas
method
block
hybrid
previous
describ
protocol
relat
array
print
hybrid
articl
gener
found
follow
link
http
catucsfeduequipmentarrayerindexhtml
rtpcr
reaction
perform
onestep
rtpcr
kit
qiagen
essenti
follow
manufactur
protocol
except
final
reaction
volum
scale
ml
forward
gtt
tcc
cag
tca
cga
tcc
agg
agg
cgg
agg
cgg
revers
primer
gtt
tcc
cag
tca
cga
tcg
gcg
ttg
tag
ctg
ggg
gtg
ag
locat
exon
erg
exon
respect
describ
end
primer
sequenc
primer
b
gtt
tcc
cag
tca
cga
tc
subsequ
step
pcr
label
singl
primer
b
describ
previous
procedur
modif
previous
report
round
abc
protocol
briefli
rtpcr
reaction
assembl
pcr
workstat
transfer
thermocycl
block
preheat
initi
revers
transcript
perform
min
follow
min
activ
hotstartaq
dna
polymeras
well
inactiv
revers
transcriptas
round
pcr
condit
cycl
min
final
extens
step
min
round
b
one
microlit
unpurifi
product
subsequ
use
templat
anoth
cycl
amplif
label
amplicon
via
previous
describ
round
c
pcr
protocol
min
primer
b
mixtur
aminoallyl
dutp
ambion
austin
tx
usa
dttp
probe
label
label
amplicon
purifi
dna
cleanup
column
zymo
research
orang
ca
usa
elut
ml
sodium
bicarbon
ph
coupl
ml
dmso
dissolv
nh
ester
ge
healthcar
piscataway
nj
usa
min
amplicon
purifi
dna
cleanup
column
elut
ml
mm
trishcl
ph
amplicon
dilut
water
combin
ml
ssc
ml
hepe
ph
final
ml
sd
reach
final
volum
ml
mix
solut
heat
min
cool
room
temperatur
hybrid
exon
map
array
overnight
essenti
previous
describ
hybrid
array
wash
scan
genepix
scanner
molecular
devic
sunnyval
ca
usa
analyz
genepix
pro
softwar
frozen
prostat
cancer
sampl
section
onto
slide
cell
nuclei
isol
situ
icecold
cytoskeleton
buffer
csk
mm
sucros
mm
nacl
mm
pipe
mm
mgcl
mm
egta
triton
slide
fix
dip
icecold
methanol
min
follow
icecold
aceton
air
dri
slide
allow
age
least
week
ethanol
dnafish
carri
accord
method
singl
copi
loci
detect
protocol
adapt
modif
use
oligonucleotid
specif
loci
interest
label
desir
hapten
two
probe
use
fish
breakapart
assay
probe
locat
promot
region
label
biotin
biogactcca
ggagcgctccccagaatccccttccttaaccca
aactcgagcc
probe
exon
erg
label
gatctttggagacccgaggaaagccgtgttga
ccaaaagcaagacaaatg
detect
probe
achiev
use
antibodi
conjug
quantum
dot
qdot
hapten
label
condit
optim
use
combin
two
antibodi
obtain
invitrogenmolecular
probe
tm
qdot
sheep
antibio
primari
antibodi
conjug
qdot
goat
antifitc
whole
igg
primari
antibodi
conjug
imag
acquisit
done
zeiss
axioplan
microscop
carl
zeiss
inc
pictur
correspond
three
channel
deconvolv
optic
section
merg
produc
pictur
use
axiovis
softwar
carl
zeiss
inc
imag
j
rasband
ws
imagej
u
nation
institut
health
bethesda
md
usa
http
rsbinfonihgovij
develop
multiplex
assay
highli
sensit
clinic
sampl
high
complex
adopt
virochip
system
key
protocol
round
abc
design
unbias
amplif
crucial
identifi
variou
fusion
variant
applic
literatur
review
found
erg
fusion
junction
exon
exon
erg
constraint
perhap
relat
whether
function
erg
protein
made
gene
fusion
therefor
initi
use
pair
primer
exon
exon
erg
rtpcr
shown
figur
pcr
product
gener
gene
fusion
sinc
two
primer
locat
differ
gene
subsequ
pcr
product
label
hybrid
exon
array
map
exon
near
fusion
junction
print
array
oligonucleotid
probe
deriv
exon
exon
erg
tabl
select
sequenc
repres
two
complementari
probe
f
forward
r
revers
complement
sinc
sometim
pcrlabel
amplicon
may
bind
one
strand
probe
base
empir
observ
observ
probe
revers
complementari
r
orient
work
consist
rtpcr
label
protocol
prostat
cancer
cell
line
vcap
erg
fusion
use
initi
feasibl
test
total
rna
subject
rtpcr
pair
primer
locat
exon
erg
exon
unpurifi
product
label
hybrid
microarray
figur
spot
correspond
exon
exon
erg
develop
strong
signal
result
indic
fusion
junction
exon
exon
erg
consist
previou
report
mimic
typic
clinic
situat
small
popul
cancer
cell
present
among
normal
host
cell
primari
tumor
spike
decreas
amount
total
rna
extract
vcap
cell
excess
hela
rna
fusion
transcript
detect
limit
pg
vcap
rna
presenc
ng
hela
rna
figur
translat
cancer
cell
presenc
time
normal
cell
level
sensit
superior
previou
method
detect
fusion
transcript
test
abil
exon
map
array
detect
character
erg
fusion
transcript
clinic
sampl
isol
total
rna
frozen
unpurifi
primari
prostat
tissu
obtain
surgeri
gggcggggagcgccgcctggagcgcggcag
acattccagatacctatcattactcgatgc
ggtcaccaccagctattggaccttactatg
tggagcgcggcaggtcatattgaacattcc
agggacatgagagaagaggagcggcgctca
agacccgaggaaagccgtgttgaccaaaag
gctggtagatgggctggcttactgaaggac
ttatcagttgtgagtgaggaccagtcgttg
ctctcctgatgaatgcagtgtggccaaagg
ctgccgcgctccaggcggcgctccccgccc
gcatcgagtaatgataggtatctggaatgt
catagtaaggtccaatagctggtggtgacc
ggaatgttcaatatgacctgccgcgctcca
tgagcgccgctcctcttctctcatgtccct
cttttggtcaacacggctttcctcgggtct
gtccttcagtaagccagcccatctaccagc
caacgactggtcctcactcacaactgataa
cctttggccacactgcattcatcaggagag
g
erg
f
forward
probe
r
revers
complement
probe
mani
tumor
substanti
fraction
normal
stromal
cell
total
rna
ng
prostat
cancer
n
nonmalign
hyperplast
prostat
tissu
n
subject
rtpcr
label
array
hybrid
result
show
cancer
nonmalign
sampl
erg
fusion
gene
confirm
presenc
gene
fusion
direct
sequenc
perform
seven
sampl
sequenc
data
valid
exon
fusion
find
reveal
array
assay
similar
report
sampl
clearli
show
two
band
agaros
gel
pcr
product
subject
electrophoresi
correspond
two
fusion
transcript
specimen
multipl
fusion
transcript
singl
prostat
cancer
sampl
may
reflect
tumor
heterogen
altern
splice
event
order
map
multipl
fusion
junction
singl
assay
redesign
exon
array
includ
junction
probe
exon
gene
exon
erg
gene
tabl
modifi
probe
set
show
clearli
patient
sampl
two
fusion
transcript
also
reveal
rel
ratio
two
fusion
transcript
respect
signal
intens
figur
case
two
fusion
transcript
exon
erg
fuse
either
exon
exon
signal
intens
junction
probe
weaker
junction
probe
figur
consist
intens
probe
within
exon
two
fusion
transcript
like
due
altern
splice
figur
summar
cluster
analysi
seven
array
result
shown
tabl
multipl
fusion
variant
found
posit
sampl
tabl
also
list
percentag
cancer
cell
tumor
gleason
tumor
grade
detect
variant
erg
fusion
transcript
small
sampl
set
clear
associ
tumor
figur
assay
sensit
vcap
total
rna
serial
dilut
solut
contain
hela
rna
mimic
heterogen
cell
popul
primari
tumor
human
bodi
fluid
total
amount
rna
reaction
ng
laser
power
pmt
output
adjust
maxim
sensit
detect
therefor
intens
expect
featur
satur
level
signal
disappear
vcap
rna
dilut
pg
pg
cctggagcgcggcagcccccgagggacatg
cctggagcgcggcaggttattccaggatct
cctggagcgcggcagccgtcaggttctgaa
cctggagcgcggcaggaagccttatcagtt
cctggagcgcggcagatgccacccccaaac
cctggagcgcggcagatcctacgctatgga
atggctttgaactcacccccgagggacatg
atggctttgaactcagttattccaggatct
atggctttgaactcaccgtcaggttctgaa
atggctttgaactcagaagccttatcagtt
atggctttgaactcaatgccacccccaaac
atggctttgaactcaatcctacgctatgga
catgtccctcgggggctgccgcgctccagg
agatcctggaataacctgccgcgctccagg
ttcagaacctgacggctgccgcgctccagg
aactgataaggcttcctgccgcgctccagg
gtttgggggtggcatctgccgcgctccagg
tccatagcgtaggatctgccgcgctccagg
catgtccctcgggggtgagttcaaagccat
agatcctggaataactgagttcaaagccat
ttcagaacctgacggtgagttcaaagccat
aactgataaggcttctgagttcaaagccat
gtttgggggtggcattgagttcaaagccat
tccatagcgtaggattgagttcaaagccat
g
erg
f
forward
probe
r
revers
complement
probe
grade
presenc
fusion
transcript
rel
larger
studi
also
show
presenc
fusion
transcript
associ
tumor
stage
tumor
grade
consist
vcap
titrat
studi
figur
clinic
assay
detect
fusion
transcript
tumor
cell
present
prostat
tissu
sampl
use
fish
analysi
independ
confirm
array
approach
fish
procedur
employ
probe
label
small
hapten
target
hybrid
conjunct
individu
haptenspecif
quantum
dot
conjug
antibodi
signal
detect
resolut
method
kb
design
two
probe
fish
assay
one
promot
region
green
figur
exon
erg
red
figur
observ
heterogen
fish
pattern
primari
prostat
cancer
sampl
figur
difficult
find
interstiti
delet
erg
tumor
sampl
contain
low
percentag
cancer
cell
fish
therefor
use
sampl
contain
cancer
cell
without
detect
fusion
gene
confirm
result
array
fish
experi
reveal
genom
delet
locat
select
sampl
similarli
nondelet
array
hybrid
establish
simpl
assay
concurr
profil
variant
erg
fusion
transcript
combin
singl
rtpcr
exon
array
modifi
round
abc
protocol
figur
cluster
analysi
seven
prostat
cancer
sampl
fusion
transcript
signal
intens
featur
divid
intens
nonspecif
control
her
sperm
dna
normal
data
cluster
analysi
result
shown
tabl
sampl
similar
fusion
transcript
variant
cluster
togeth
program
figur
heterogen
fish
pattern
interstiti
delet
erg
primari
prostat
tumor
unpair
green
dot
probe
indic
arrow
suggest
interstiti
delet
nonrandom
variat
fish
pattern
shown
fact
green
red
signal
two
differ
nearbi
probe
pair
panel
variat
expect
heterogen
aneuploid
cancer
cell
popul
often
make
difficult
distinguish
meaning
event
random
background
aberr
origin
design
genom
amplif
wide
adopt
chromatin
immunoprecipit
chip
wholegenom
dna
microarray
chipchip
virochip
experi
simpl
rel
unbias
amplif
procedur
semiquantit
measur
fusion
variant
complex
sampl
previous
simpl
procedur
use
obtain
kb
sar
coronaviru
genom
total
nucleic
acid
isol
viral
cultur
inclus
within
array
probe
deriv
individu
exon
potenti
fusion
junction
simplifi
breakpoint
map
increas
confid
data
interpret
figur
contrast
report
use
multipl
primer
target
everi
potenti
fusion
junction
hematolog
malign
use
singl
set
primer
target
amplif
figur
fusion
junction
subsequ
decod
array
design
significantli
reduc
problem
associ
primer
dimer
multiplex
pcr
reaction
creat
room
futur
assay
includ
addit
fusion
gene
furthermor
search
fusion
gene
focus
blood
cancer
cell
purifi
analysi
applic
previou
methodolog
less
use
highli
complex
solid
tumor
inevit
admix
normal
cell
exampl
previous
report
mllfusionchip
could
appli
sampl
cancer
cell
mg
total
rna
current
assay
facilit
thorough
compil
gene
fusion
variant
primari
prostat
specimen
may
use
stratifi
aggress
prostat
cancer
regard
fusion
variant
ew
anoth
member
et
famili
shown
independ
predictor
diseas
progress
ewe
sarcoma
interest
compar
transfect
cell
biolog
activ
differ
erg
variant
patient
contrast
clinic
outcom
studi
suggest
presenc
erg
fusion
associ
aggress
diseas
higher
gleason
tumor
grade
investig
reach
conclus
also
find
associ
small
seri
sampl
howev
result
defect
due
small
sampl
size
technolog
describ
make
possibl
larger
scale
investig
find
whether
correl
aggress
diseas
presenc
specif
fusion
gene
crucial
true
cancerspecif
biomark
earli
cancer
detect
well
minim
residu
diseas
monitor
extens
demonstr
hematolog
malig
biomark
could
help
avoid
underor
overtreat
thu
past
interest
appli
erg
fusion
assay
applic
sinc
psa
mani
marker
develop
truli
prostat
cancerspecif
recent
studi
report
erg
assay
sensit
detect
vcap
cell
howev
level
sensit
might
suffici
broad
clinic
applic
especi
small
biopsi
specimen
urin
sampl
abl
achiev
assay
sensit
pg
total
rna
deriv
vcap
cell
equival
cell
figur
assay
simpl
amen
autom
readili
adapt
clinic
studi
challeng
adapt
microarraybas
technolog
clinic
test
eg
amplichip
mammaprint
approv
fda
strategi
appli
detect
less
preval
fusion
transcript
prostat
cancer
addit
exon
array
approach
also
appli
fusion
gene
bcrabl
cml
clonal
igtcr
rearrang
lymphocyt
malign
methodolog
develop
motiv
clinic
need
gener
applic
research
requir
analog
situat
detect
fusion
gene
singl
cell
level
larg
excess
normal
cell
present
exampl
development
biologist
may
use
similar
approach
screen
mutant
desir
gene
fusion
direct
gene
target
feasibl
shortcom
use
rna
transcript
prostat
cancer
biomark
despit
abil
achiev
sensit
detect
erg
fusion
variant
first
rna
unstabl
difficult
process
routin
clinic
assay
second
commonli
use
drug
inhibit
androgen
growth
pathway
includ
gnrh
agonist
testosteron
antagonist
may
diminish
product
erg
mrna
fusion
transcript
therebi
produc
falseneg
result
patient
hormon
therapi
evolv
androgenindepend
tumor
inde
report
erg
mrna
fusion
transcript
express
androgenindepend
tumor
spite
presenc
interstiti
delet
erg
chromosom
fish
use
identifi
genom
rearrang
rel
lower
resolut
difficult
use
highli
heterogen
sampl
small
percentag
tumor
cell
recent
develop
technolog
design
primer
approxim
multiplex
pcr
pamp
identifi
breakpoint
genom
dna
without
need
purifi
cancer
cell
normal
tissu
optim
assay
detect
breakpoint
erg
loci
primari
prostat
tumor
overcom
potenti
problem
associ
rna
base
biomark
addit
dnabas
assay
provid
inform
whether
multipl
fusion
transcript
sampl
deriv
altern
splice
tumor
heterogen
best
approach
may
ultim
combin
dna
rna
base
assay
common
format
institut
health
ucsd
nanotumor
center
excel
cancer
nanotechnolog
liu
